Surveillance and AI-Powered Prediction of AMR to Inform Antibiotic Therapy

Presented By: Arne Materna, PhD Speaker Biography: Dr. Arne Materna is Managing Director and CEO of Ares Genetics. Dr. Materna brings a wealth of experience in the development and commercialization of leading-edge bioinformatics platforms and products with a particular focus on microbiology and next-generation sequencing. He joined Ares Genetics from CosmosID Inc. where he served as Vice President Product. Before CosmosID, Dr. Materna held leadership positions and senior roles at QIAGEN, CLCbio (acquired by QIAGEN in 2013) and Pacific Biosciences. He obtained his doctorate in life science at the University of Konstanz, Germany, and gained experience in microbial genetics and microbiome research as a post-doctoral fellow at the Massachusetts Institute of Technology (MIT), prior to joining the industry in 2010. Webinar: Surveillance and AI-Powered Prediction of AMR to Inform Antibiotic Therapy Webinar Abstract: The burden of antimicrobial resistance (AMR) has been acknowledged worldwide by leading health institutes. Besides the need for new antibiotics, efforts are required in the field of AMR surveillance and diagnostics for effective infection prevention and empirically informed selection of first line treatments. Next-generation sequencing (NGS), has emerged as an alternative to established molecular tests for the detection, identification, typing and functional characterization of AMR pathogens. The advantage of NGS over other tests resides in the technique’s potential to integrate into a single assay i) the sensitive and comprehensive detection of pathogens with ii) the characterization of AMR based on genomic information. Yet, several limitations impair adoption of NGS for AMR testing, including a lack of validated NGS and bioinformatics workflows, as well as slow turnaround times associated with NGS. For complex sample types such as native patient or environmental specimen, common in culture-free testing, high concentrations of background DNA relative to pathogen DNA further diminishes the utility of the technology. To overcome the aforementioned challenges, we have designed a set of isolate-based and culture-free assays for the identification and characterization of AMR pathogens. In this talk, we present our findings from the routine application of these assays in our lab and explore the results from their clinical validation. Earn PACE Credits: 1. Make sure you're a registered member of LabRoots (https://www.labroots.com/ms/webinar/s...) 2. Watch the webinar on the LabRoots Website (https://www.labroots.com/ms/webinar/s...) 3. Click Here to get your PACE credits (Expiration date – DEC 09, 2023): (https://www.labroots.com/credit/pace-...) LabRoots on Social: Facebook:   / labrootsinc   Twitter:   / labroots   LinkedIn:   / labroots   Instagram:   / labrootsinc   Pinterest:   / labroots   SnapChat: labroots_inc